1. NIH Consensus Conference. JAMA 1993; 270 (1): 83–90.
2. Feldman HA, Goldstein I, Hatzichristou DG et al. Impotence and its medical and psychosocial correlates: results of the Massachusetts male aging study. J Urol 1994; 151: 54–61.
3. Rosen RC, Fisher WA, Eardley I et al. Men's Attitudes to Life Events and Sexuality (MALES) Study. The multinational Men's Attitudes to Life Events and Sexuality (MALES) study: I. Prevalence of erectile dysfunction and related health concerns in the general population. Curr Med Res Opin 2004; 20 (5): 607–17.
4. Глыбочко П.В., Аляев Ю.Г., Ахвледиани Н.Д. и др. Практическая урология. Руководство для врачей. М.: Медфорум, 2012; с. 265–95.
5. Отчет Gfk. Custom Research, 2011.
6. Zhang K, He ZJ, Xin ZC et al. Physicians' knowledge and attitude to erectile dysfunction. Zhonghua Nan KeXue 2002; 8 (3): 181–5.
7. Holden CA, Jolley DJ, McLachlan RI et al. Men in Australia Telephone Survey (MATeS): predictors of men's help-seeking behaviour for reproductive health disorders. Med J Aust 2006; 185 (8): 418–22.
8. Baldwin K, Ginsberg P, Harkaway RC. Under-reporting of erectile dysfunction among men with unrelated urologic conditions. Int J Impot Res 2003; 15 (2): 87–9.
9. Montorsi P, Ravagnani PM, Galli S et al. Curr Opin Urol 2004; 14 (6): 361–5.
10. Martin-Morales A, Sanchez-Cruz JJ, Saenz de Tejada I et al. Prevalence and independent risk factors for erectile dysfunction in Spain: results of the Epidemiologia de la Disfuncion Erectile Masculina Study. J Urol 2001; 166 (2): 569–74.
11. Braun M, Wassmer G, Klotz T et al. Epidemiology of erectile dysfunction: results of the 'Cologne Male Survey'. Int J Impot Res 2000; 12 (6): 305.
12. Goldstein I. The mutually reinforcing triad of depressive symptoms, cardiovascular disease, and erectile dysfunction. Am J Cardiol 2000; 86 (2A): 41F–45F.
13. Baumgartner MK, Hermanns T, Cohen A et al. Patients‘knowledge about risk factors for erectile dysfunction is poor. J Sex Med 2008; 5 (10): 2399–404.
14. Wespes E, Amar E, Eardley I et al. Guidelines on Male Sexual Dysfunction: Erectile dysfunction and premature ejaculation EAU Guidelines 2011; p. 4–47.
15. Martin-Morales A, Haro JM, Beardsworth A et al. EDOS Group. Therapeutic effectiveness and patient satisfaction after 6 months of treatment with tadalafil, sildenafil, and vardenafil: results from the erectile dysfunction observational study (EDOS). Eur Urol 2007; 51 (2): 541–50.
16. Chun J, Carson CC. Physician-patient dialogue and clinical evaluation of erectil dysfunction. Urol Clin North Am 2001; 28: 249–58.
17. Perelman MA. Sex coaching for physicians: Combination treatment for patient and partner. Int J Impot Res 2003; 15 (Suppl. 5): S67–74.
18. Rosen RC, Fisher WA, Eardley I et al. Men's Attitudes to Life Events and Sexuality (MALES) Study. The multinational Men's Attitudes to Life Events and Sexuality (MALES) study: Prevalence of erectile dysfunction and related health concerns in the general population. Curr Med Res Opin 2004; 20 (5): 607–17.
19. Holden CA, Jolley DJ, McLachlan RI et al. Men in Australia Telephone Survey (MATeS): predictors of men's help-seeking behaviour for reproductive health disorders. Med J Aust 2006; 185 (8): 418–22.
20. Wright PJ. Comparison of phosphodiesterase type 5 (PDE5) inhibitors. Int J Clin Pract 2006; 60 (8): 967–75.
21. Kim TE, Kim BH, Kim JR et al. Effect of food on the pharmacokinetics of the oral phosphodiesterase 5-inhibitor udenafil for the treatment of erectile dysfunction. Br J Clin Pharmacol 2009; 68 (1): 43–6.
22. Lee J, Pommerville P, Brock G et al. Physician-rated patient preference and patient- and partner-rated preference for tadalafil or sildenafil citrate: results from the Canadian 'Treatment of Erectile Dysfunction' observational study. BJU Int 2006; 98 (3): 623–9.
23. Fisher WA, Rosen RC, Eardley I et al. Sexual experience of female partners of men with erectile dysfunction: the female experience of men's attitudes to life events and sexuality (FEMALES) study. J Sex Med 2005; 2 (5): 675–84.
24.Dunn ME, Althof SE, Perelman MA. Phosphodiesterase type 5 inhibitors extendedduration of response as a variable in the treatment of erectile dysfunction. Int J Impot Res 2007; 19 (2): 119–23.
25. Washington SL, Shindel AW. A once-daily dose of tadalafil for erectile dysfunction: compliance and efficacy. Drug Des Devel Ther 2010; 4: 159–71.
26. Инструкция для специалистов по медицинскому применению препарата Сиалис® 20 мг (тадалафил), П №014761/01-050309.
27. Инструкция для специалистов по медицинскому применению препарата Сиалис® 5 мг (тадалафил), ЛП-000133 от 11.01.2011.
28. Seftel A, Goldfischer E, Kim ED et al. Onset of efficacyof tadalafil once daily in men with erectile dysfunction: a randomized,double-blind, placebo controlled trial. J Urol 2011; 185 (1): 243–8.
29. Porst H, Giuliano F, Glina S et al. Evaluation of the efficacy and safety of once-a-day dosing oftadalafil 5mg and 10mg in the treatment of erectile dysfunction: results of amulticenter, randomized, double-blind, placebo-controlled trial. Eur Urol 2006; 50 (2): 351–9.
30. Carson CC, Rajfer J, Eardley I et al. The efficacy and safety of tadalafil: an update. BJU Int 2004; 93 (9): 1276–81.
31. Porst H, Rajfer J, Casabé A et al. Long-term safety and efficacy of tadalafil 5 mg dosed once daily inmen with erectile dysfunction. J Sex Med 2008; 5 (9): 2160–9.
32. Rubio-Aurioles E, Porst H, Kim ED et al. A RandomizedOpen-Label Trial with a Crossover Comparison of Sexual Self-Confidence and Other Treatment Outcomes Following Tadalafil Once a Day Vs. Tadalafil or SildenafilOn-Demand in Men with Erectile Dysfunction. J Sex Med 2012; 9 (5): 1418–29.

Н.Д.Ахвледиани 

Кафедра урологии ГБОУ ВПО Первый МГМУ им. И.М.Сеченова Минздрава РФ